Pharmacodynamics of amphotericin B in a neutropenic-mouse disseminated-candidiasis model
about
Population pharmacokinetics of liposomal amphotericin B in pediatric patients with malignant diseasesPharmacokinetics and pharmacodynamics of antifungals in children: clinical implicationsInteraction between posaconazole and amphotericin B in concomitant treatment against Candida albicans in vivoAntifungal susceptibility testing: practical aspects and current challenges.Method for measuring postantifungal effect in Aspergillus species.Penetration of drugs through the blood-cerebrospinal fluid/blood-brain barrier for treatment of central nervous system infections.Itraconazole preexposure attenuates the efficacy of subsequent amphotericin B therapy in a murine model of acute invasive pulmonary aspergillosis.Pharmacodynamic activity of amphotericin B deoxycholate is associated with peak plasma concentrations in a neutropenic murine model of invasive pulmonary aspergillosisPharmacokinetic-pharmacodynamic comparison of amphotericin B (AMB) and two lipid-associated AMB preparations, liposomal AMB and AMB lipid complex, in murine candidiasis models.Time course of microbiologic outcome and gene expression in Candida albicans during and following in vitro and in vivo exposure to fluconazole.In vivo pharmacodynamics of HMR 3270, a glucan synthase inhibitor, in a murine candidiasis model.In vivo pharmacodynamics of antifungal drugs in treatment of candidiasis.Pharmacodynamic target evaluation of a novel oral glucan synthase inhibitor, SCY-078 (MK-3118), using an in vivo murine invasive candidiasis model.Antifungal pharmacokinetics and pharmacodynamicsNontoxic antimicrobials that evade drug resistance.Update in the epidemiology, prophylaxis, and treatment of fungal infections in patients with hematologic disorders.Commentary: pediatric antifungal drug development: lessons learned and recommendations for the future.Management of invasive pulmonary aspergillosis in non-neutropenic critically ill patientsOptimization of the dosage of flucytosine in combination with amphotericin B for disseminated candidiasis: a pharmacodynamic rationale for reduced dosingPopulation pharmacokinetics of conventional and intermittent dosing of liposomal amphotericin B in adults: a first critical step for rational design of innovative regimensIn vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model.Pharmacodynamics and dose-response relationships of liposomal amphotericin B against different azole-resistant Aspergillus fumigatus isolates in a murine model of disseminated aspergillosisIn vivo pharmacodynamic target investigation for micafungin against Candida albicans and C. glabrata in a neutropenic murine candidiasis model.Safety of aerosolized amphotericin B.High-dose weekly AmBisome antifungal prophylaxis in pediatric patients undergoing hematopoietic stem cell transplantation: a pharmacokinetic studyAntifungal therapeutic drug monitoring: established and emerging indications.Pharmacokinetics and buccal mucosal concentrations of a 15 milligram per kilogram of body weight total dose of liposomal amphotericin B administered as a single dose (15 mg/kg), weekly dose (7.5 mg/kg), or daily dose (1 mg/kg) in peripheral stem celSafety, Tolerability, and Pharmacokinetics of Liposomal Amphotericin B in Immunocompromised Pediatric Patients.Continuous infusion of amphotericin B deoxycholate: an innovative, low-cost strategy in antifungal treatment.Invasive fungal infections in the ICU.Amphotericin B use in children: conventional and lipid-based formulations.Current concepts in antifungal pharmacology.Pharmacokinetics and pharmacodynamics of antifungals in children and their clinical implications.Therapeutic drug monitoring for invasive mould infections and disease: pharmacokinetic and pharmacodynamic considerations.AmBisome: relationship between the pharmacokinetic characteristics acquired by liposomal formulation and safety/efficacy.Pharmacodynamic Optimization for Treatment of Invasive Candida auris Infection.Antifungal Efficacy of an Intravenous Formulation Containing Monomeric Amphotericin B, 5-Fluorocytosine, and Saline for Sodium Supplementation.Antifungal therapies in murine infections by Candida kefyr.Efficacy of Extended-Interval Dosing of Micafungin Evaluated Using a Pharmacokinetic/Pharmacodynamic Study with Humanized Doses in Mice.In vitro pharmacodynamics of rapid versus continuous infusion of amphotericin B deoxycholate against Candida species in the presence of human serum albumin.
P2860
Q24542404-39902490-F7FB-4B05-A537-945F3A289D88Q27025299-F322319C-4236-43C2-901E-E2337D7C0C4CQ33803508-8D085423-D1C8-406B-8924-3C93AB88D2F0Q33975757-47590951-8EA8-4F7C-9126-1B3F7DC28A2FQ34108018-16072CE4-E039-48D9-B75C-65DA5F6A65D7Q34142328-1FA35D50-89B7-4165-8AC2-3F732E135372Q34143326-2CAA3F43-43E6-4080-BD2E-7CD8D836AB71Q34352109-4CE0870E-D499-47CC-89CB-6DF09AABBAE9Q34352186-D3E25249-9BF1-4CD9-AB18-47D98FAFB9BAQ34510556-21A2A16E-4639-4B81-BA0B-5FB08C4B14ABQ34881309-CDF28872-34C1-4567-A28B-9371BA9CD1ADQ35091285-A9ADFB68-923B-44E3-AE33-AAC34E6043BDQ35105763-03DA77BE-35C1-4088-9932-867F9510B418Q35663841-B807900C-B390-413D-A3F7-359337E52A53Q35756422-E4D350F8-2644-49F5-9ECA-C96CA19641F1Q35782575-32453866-476D-4661-96DF-C93F157A8D94Q35973357-9F010D08-4A76-4F9C-8009-2C4E99496778Q36087577-B67169C0-9224-44A8-A9CD-96588349E722Q36094962-210480A0-0025-4190-A59E-7284AB3758E8Q36276870-F2C4CEF8-342A-4FD8-9603-314377C75EA0Q36425025-959DED3C-66AF-427C-895E-875D369CF189Q36757621-0BC41D63-ED78-4BFB-A4C4-715BF79ECF85Q36932989-E58626EB-4105-4C5A-96F4-A72D3E928774Q36945011-637ABB09-D53B-4233-83E1-5C89DAB79023Q37016279-0CE7C112-4069-4FAA-AAA1-9A639058F2C8Q37310029-6B3AD532-F828-4CB9-8584-6DA306CB0FDCQ37333175-BD578E9A-B2AF-4D29-B8C4-EC8430C1081DQ37613070-4F98426B-9395-4FB4-A80F-97DBE2849F21Q37624898-A316EFFE-EEED-4D85-82CA-F022CD6A8482Q37643057-743CAD26-5015-4C13-AB56-55E56C74CE5BQ37854727-0AC7D691-C972-4D2C-9C9D-A39356AAB755Q37908856-5D9830B2-25EB-4961-AE9A-6D1FFBF8AEDFQ38193337-2899A8E6-432B-48DD-B561-E896B150E26CQ38738090-B6CB2FB7-D59B-4BB3-821C-B89E729231C7Q38872275-9C5B33E2-0CA4-4300-B21D-2DF2CA879602Q39092240-7738C8A6-5ED6-419E-8C62-D23607A22BA3Q40330676-079628B0-3F9C-435D-AF4F-E7D9E1926D20Q40799658-CB7DA3EC-D0A7-49A4-8467-12DA0EC425FAQ40916536-F74BFCFB-79E4-44ED-AE3F-BA4D02614E66Q42676999-721460C8-D2B9-4578-B0A9-53F5E02654C9
P2860
Pharmacodynamics of amphotericin B in a neutropenic-mouse disseminated-candidiasis model
description
2001 nî lūn-bûn
@nan
2001 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի մարտին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Pharmacodynamics of amphotericin B in a neutropenic-mouse disseminated-candidiasis model
@ast
Pharmacodynamics of amphotericin B in a neutropenic-mouse disseminated-candidiasis model
@en
type
label
Pharmacodynamics of amphotericin B in a neutropenic-mouse disseminated-candidiasis model
@ast
Pharmacodynamics of amphotericin B in a neutropenic-mouse disseminated-candidiasis model
@en
prefLabel
Pharmacodynamics of amphotericin B in a neutropenic-mouse disseminated-candidiasis model
@ast
Pharmacodynamics of amphotericin B in a neutropenic-mouse disseminated-candidiasis model
@en
P2093
P2860
P1476
Pharmacodynamics of amphotericin B in a neutropenic-mouse disseminated-candidiasis model
@en
P2093
P2860
P304
P356
10.1128/AAC.45.3.922-926.2001
P407
P577
2001-03-01T00:00:00Z